This may allow quantitative assessment of the efficacy of different (future) therapeutic options, and hence propose a phenotype-based therapeutic approach for NP-C patients based on the classification of NPC1 mutants. This evidence concerns the gene NPC1 and nasopharyngeal carcinoma.